Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q4 EPS of ($0.02), $0.02 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $11.65 million versus the consensus estimate of $10.8 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.